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Following the submission of application EFSA-GMO-RX-015 under Regulation (EC) No 1829/2003 from
Bayer Agriculture BVBA, the EFSA Panel on Genetically Modiﬁed Organisms (GMO Panel) was asked to
deliver a scientiﬁc risk assessment on the data submitted in the context of the renewal of authorisation
application for the insect-resistant genetically modiﬁed maize MON 89034, for food and feed uses,
excluding cultivation within the EU. The data received in the context of this renewal application contained
post-market environmental monitoring reports, a systematic search and evaluation of literature, updated
bioinformatic analyses and additional documents or studies performed by or on behalf of the applicant.
The GMO Panel assessed these data for possible new hazards, modiﬁed exposure or new scientiﬁc
uncertainties identiﬁed during the authorisation period and not previously assessed in the context of the
original application. Under the assumption that the DNA sequence of the event in maize MON 89034
considered for renewal is identical to the sequence of the originally assessed event, the GMO
Panel concludes that there is no evidence in renewal application EFSA-GMO-RX-015 for new hazards,
modiﬁed exposure or scientiﬁc uncertainties that would change the conclusions of the original risk
assessment on maize MON 89034.
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Summary
Following the submission of application EFSA-GMO-RX-015 under Regulation (EC) No 1829/20031
from Bayer Agriculture BVBA, the EFSA Panel on Genetically Modiﬁed Organisms (GMO Panel) was
asked to deliver a scientiﬁc risk assessment on the data submitted in the context of the renewal of
authorisation application for the insect-resistant genetically modiﬁed (GM) maize MON 89034. The
scope of the renewal application EFSA-GMO-RX-015 is for the renewal of the placing on the market of
products containing, consisting of, or produced from maize MON 89034, excluding cultivation within
the European Union (EU).
In delivering its scientiﬁc opinion, the GMO Panel took into account application EFSA-GMO-RX-015,
additional information provided by the applicant, scientiﬁc comments submitted by the EU Member
States and relevant scientiﬁc publications. The data received in the context of the renewal application
EFSA-GMO-RX-015 contained: post-market environmental monitoring reports, an evaluation of the
literature retrieved by a systematic search, updated bioinformatics analyses and additional studies
performed by or on behalf of the applicant. The GMO Panel assessed these data for possible new
hazards, modiﬁed exposure or new scientiﬁc uncertainties identiﬁed during the authorisation period
and not previously assessed in the context of the original application.
Under the assumption that the DNA sequence of the event in maize MON 89034 considered for
renewal is identical to the sequence of the originally assessed event, the GMO Panel concludes that
there is no evidence in the renewal application EFSA-GMO-RX-015 for new hazards, modiﬁed exposure
or scientiﬁc uncertainties that would change the conclusions of the original risk assessment on maize
MON 89034 (EFSA, 2008).
1 Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modiﬁed
food and feed. OJ L 268, 18.10.2003, p. 1–23.
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1. Introduction
1.1. Background
On 29 August 2018, the European Food Safety Authority (EFSA) received from the European
Commission (EC) application EFSA-GMO-RX-015 for the renewal of the authorisation of maize
MON 89034 (Unique Identiﬁer MON-89Ø34-3), submitted by Bayer Agriculture BVBA (hereafter
referred to as ‘the applicant’) according to Regulation (EC) No 1829/2003.2
Following receipt of application EFSA-GMO-RX-015, EFSA informed the Member States (MS) and
made the summary of the application available to the public on the EFSA website.3
EFSA checked the application for compliance with the relevant requirements of Regulation
(EC) No 1829/2003 and Regulation (EU) No 503/20134 and, when needed, asked the applicant to
supplement the initial application. On 4 December 2018, EFSA declared the application valid and made
the valid application available to the MS and the European Commission.
Following the submission of application EFSA-GMO-NL-2007-37 and the publication of the EFSA
scientiﬁc opinion (EFSA, 2008), the placing on the market of maize MON 89034 for products containing,
consisting of, or produced from this genetically modiﬁed (GM) maize, excluding cultivation in the EU, was
authorised by Commission Decision 2009/813/EC.5 A copy of this authorisation was provided by the
applicant.6
From the validity date, EFSA and its scientiﬁc Panel on Genetically Modiﬁed Organisms (hereafter
referred to as ‘the GMO Panel’) endeavoured to respect a time limit of 6 months to issue a scientiﬁc
opinion on application EFSA-GMO-RX-015. Such time limit was extended whenever EFSA and/or its
GMO Panel requested supplementary information to the applicant. According to Regulation
(EC) No 1829/2003, any supplementary information provided by the applicant during the risk
assessment was made available to the MS and European Commission (for further details, see the section
‘Documentation’, below).
In accordance with Regulation (EC) No 1829/2003, EFSA consulted the nominated risk assessment
bodies of the MS, including national Competent Authorities within the meaning of Directive 2001/18/
EC.7 The MS had three months to make their opinion known on application EFSA-GMO-RX-015 as of
date of validity.
1.2. Terms of Reference as provided by the requestor
According to Articles 6 and 18 of Regulation (EC) No 1829/2003, EFSA and its GMO Panel were
requested to carry out a scientiﬁc risk assessment of maize MON 89034 for the renewal of
authorization for placing on the market of products containing, consisting of, or produced from GM
maize MON 89034 in the context of its scope as deﬁned in application EFSA-GMO-RX-015.
According to Regulation (EC) No 1829/2003, this scientiﬁc opinion is to be seen as the report
requested under Articles 6(6) and 18(6) of that Regulation including the opinions of the nominated risk
assessment bodies of the MS.8
In addition to the present scientiﬁc opinion on maize MON 89034, EFSA and its GMO Panel were also
asked to report on the particulars listed under Articles 6(5) and 18(5) of Regulation (EC) No 1829/2003.
The relevant information is made available in the EFSA Register of Questions,9 including the information
required under Annex II to the Cartagena Protocol, a labelling proposal, a Post-Market Environmental
Monitoring plan as provided by the applicant; the method(s), validated by the Community reference
2 Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modiﬁed
food and feed. OJ L 268, 18.10.2003, p. 1–23.
3 Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionDocumentsLoader?question=EFSA-Q-2018-00673
4 Commission Implementing Regulation (EU) No 503/2013 of 3 April 2013 on applications for authorisation of genetically
modiﬁed food and feed in accordance with Regulation (EC) No 1829/2003 of the European Parliament and of the Council and
amending Commission Regulations (EC) No 641/2004 and (EC) No 1981/2006. OJ L157, 8.6.2013, p. 1–48.
5 Commission Decision of 30 November 2009 authorising the placing on the market of products containing, consisting of, or
produced from genetically modiﬁed maize MON 89034 (MON-89Ø34-3) pursuant to Regulation (EC) No 1829/2003 of the
European Parliament and of the Council. Ofﬁcial Journal of the European Union L 314/102, 30.11.2009.
6 Dossier: Maize MON 89034 – Annex 1.
7 Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the
environment of genetically modiﬁed organisms and repealing Council Directive 90/220/EEC. OJ L 106, 12.3.2001, p. 1–38.
8 Opinions of the nominated risk assessment bodies of EU Member States can be found at the EFSA Register of Questions,
9 http://registerofquestions.efsa.europa.eu/roqFrontend/questionDocumentsLoader?question=EFSA-Q-2018-00673
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laboratory, for detection, including sampling, identiﬁcation of the transformation event in the food-feed
and/or foods-feeds produced from it and the appropriate reference materials.
2. Data and methodologies
2.1. Data
The data for application EFSA-GMO-RX-015 provided by the applicant at the time of submission, or
in reply to requests for additional information, are speciﬁed below.
In the context of this renewal application, no new sequencing study was submitted among the
additional documents or studies performed by or on behalf of the applicant. In accordance with the
GMO Panel guidelines for renewal of applications of GM food and feed authorised under
Regulation (EC) No 1829/2003 (EFSA GMO Panel, 2015), the GMO Panel evaluated the data provided
in the context of this maize MON 89034 renewal application under the assumption that the
MON 89034 event sequence is identical to the sequence of the originally assessed event (EFSA, 2008).
2.1.1. Post-market monitoring reports10
Based on the outcome of the initial food and feed risk assessment, a post-market monitoring plan
for monitoring of GM food and feed was not required by the authorisation decision. The
implementation of a post-market environmental monitoring (PMEM) plan, consisting of a general
surveillance plan to check for any adverse effects on the environment arising from maize MON 89034,
was a condition for the authorisation. As no potential adverse environmental effects were identiﬁed in
the environmental risk assessment of maize MON 89034 (EFSA, 2008), case-speciﬁc monitoring was
not considered necessary by the GMO Panel.
The applicant provided nine annual PMEM reports covering a reporting period from July 2009 till
July 2018. The annual PMEM plans submitted by the applicant included (1) commodity crop (GM and
non-GM) imports into the EU by country of origin and destination; (2) the description of a centralised
system established by EuropaBio for the collection of information recorded by various operators
(federations involved in maize grains import and processing) on any observed adverse effect(s) on
human health and the environment arising from handling of maize possibly containing maize
MON 89034; (3) the reports of the surveillance activities conducted by such operators; and (4) the
review of relevant scientiﬁc peer-reviewed studies retrieved from literature searches.
2.1.2. Systematic search and evaluation of literature11
In addition to the separate searches provided as part of the annual PMEM reports, the applicant
performed a systematic literature search covering the period from January 2008 till June 2018, in
accordance with the recommendations on literature search outlined in EFSA (2010, 2017a).
Searches in electronic bibliographic databases and in websites of relevant organisations were
performed to identify relevant publications. Altogether, 285 publications were identiﬁed (after removal
of duplicates).12 After applying the eligibility/inclusion criteria deﬁned a priori by the applicant, ﬁve
publications were identiﬁed as relevant for food and feed safety assessment or molecular
characterisation. The list of relevant publications is provided in Appendix A.
2.1.3. Updated bioinformatic data13
At the time of submission of the renewal dossier, the applicant provided a complete bioinformatic
dataset for maize MON 89034 event including an analysis of the insert and ﬂanking sequences, an
analysis of the potential similarity to allergens and toxins of the newly expressed proteins and of all
possible open reading frames (ORFs) within the insert and spanning the junction sites, an analysis of
possible horizontal gene transfer (HGT) (EFSA, 2017b), and a safety assessment of the newly
expressed proteins Cry1A.105 and Cry2Ab2 regarding their capacity to trigger celiac disease (EFSA
GMO Panel, 2017a). Upon EFSA request, the applicant provided additional information followed by
10 Dossier: Maize MON 89034 – Annex 2; additional information: 21/2/2019.
11 Dossier: Maize MON 89034 – Annex 3.1; additional information: 21/2/2019.
12 One hundred seventy-eight publications were identiﬁed in Web of ScienceTM Core Collection database and 107 publications
were identiﬁed in CAB Abstracts® database.
13 Dossier: Maize MON 89034 – Annex 3.2; additional information: 22/5/2019 and 19/6/2019.
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further clariﬁcations on the celiac disease analysis for Cry1A.105 protein. The outcome of the updated
bioinformatic analyses is presented in Section 3.3.
2.1.4. Additional documents or studies provided by the applicant14
In line with the renewal guidance requirements (EFSA GMO Panel, 2015), the applicant provided an
overview on the worldwide approvals of maize MON 89034 and searched for any available full reports
of studies performed by or on behalf of the applicant over the course of the authorisation period and
not previously submitted to the EU.
2.1.5. Overall assessment as provided by the applicant15
The applicant provided an overall assessment concluding that information provided in the
application for renewal of authorisation of maize MON 89034 for food and feed uses in the EU does
not change the outcome of the original risk assessment (EFSA, 2008).
2.1.6. Monitoring plan and proposal for improving the conditions of the original
authorisation15
The applicant indicated in the dossier that the environmental post-market monitoring plan is
appropriate and does not need any changes.
2.2. Methodologies
The GMO Panel assessed the application for renewal of the authorisation of maize MON 89034 for
food and feed uses in accordance with Articles 11 and 23 of Regulation (EC) No 1829/2003. The GMO
Panel took into account the requirements described in its guideline for the risk assessment of renewal
applications of GM food and feed authorised under Regulation (EC) No 1829/2003 (EFSA GMO Panel,
2015). The comments raised by the nominated risk assessment bodies of EU MS were taken into
consideration during the scientiﬁc risk assessment.9
3. Assessment
3.1. Evaluation of the post-market monitoring reports
During the general surveillance activities covering the authorisation period of maize MON 89034, no
adverse effects were reported by the applicant.
3.2. Evaluation of the systematic search and evaluation of literature
The GMO Panel assessed the applicant’s literature search on maize MON 89034 and the newly
expressed proteins Cry1A.105 and Cry2Ab2. The overall quality of the performed literature search is
acceptable; however, the GMO Panel considers that future searches could be improved. The GMO
Panel recommends the applicant for future searches to:
• ensure that enough search term variation is used (covering possible synonyms, related terms,
acronyms, spelling variants, old and new terminology, brand and generic names, lay and
scientiﬁc terminology, common typos, translation issues);
• adapt the search to the size of the retrieved publications (and thus not combine search sets
when one of the search sets already yields only a small number of publications)
The GMO Panel acknowledges that no publications raising a safety concern for human and animal
health and the environment which would change the original risk assessment conclusions on maize
MON 89034 (EFSA, 2008) have been identiﬁed by the applicant.
3.3. Evaluation of the updated bioinformatic data
The results of the updated bioinformatic analyses of maize MON 89034 conﬁrm that no known
endogenous genes were disrupted by the insert. Analyses of the amino acid sequence of the newly
14 Dossier: Maize MON 89034 – Annex 3.3.
15 Dossier: Maize MON 89034 – Annex 4.
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expressed Cry1A.105 and Cry2Ab2 proteins reveal no signiﬁcant similarities to toxins, allergens or
immunogenic gluten-related epitopes. In addition, bioinformatic analyses of the newly created ORFs
within the insert or spanning the junctions with genomic DNA conﬁrm the previous conclusions
indicating that the expression of an ORF showing signiﬁcant similarities to toxins or allergens for the
event MON 89034 is highly unlikely (EFSA, 2008; EFSA GMO Panel, 2017b,c, 2019a,b).
The updated bioinformatic analysis for maize event MON 89034 do not reveal any new DNA
sequence that could provide sufﬁcient length and identity which could facilitate HGT by double
homologous recombination (HR) conﬁrming the previous conclusions (EFSA GMO Panel, 2017b,c,
2019a,b). Given the results of this analysis and that the recombinant DNA in maize MON 89034 does
not confer selective advantages or increased ﬁtness to microorganisms, the GMO Panel identiﬁed no
safety concern linked to an unlikely but theoretically possible HGT.
3.4. Evaluation of the additional documents or studies provided by the
applicant
Taking into account (i) the relevance for molecular characterisation, human and animal safety and
the environment; and (ii) the scope of this renewal application, there are no unpublished studies
available performed by the applicant and not previously submitted to the EU since MON 89034 was
authorised.
3.5. Evaluation of the overall assessment as provided by the applicant
The GMO Panel evaluated the overall assessment provided by the applicant and conﬁrms that there
is no evidence in renewal application EFSA-GMO-RX-015 indicating new hazards, relevant changes in
exposure or scientiﬁc uncertainties that would change previous conclusions on maize MON 89034.
3.6. Evaluation of the monitoring plan and proposal for improving the
conditions of the original authorisation
The PMEM plan covers general surveillance of imported GM plant material, including maize
MON 89034. This general surveillance is coordinated by EuropaBio and implemented by selected
operators (federations involved in maize grains import and processing). In addition, the applicant
reviews relevant scientiﬁc publications retrieved from literature searches on an annual basis. The GMO
Panel is of the opinion that the scope of the plan provided by the applicant is consistent with the
scope of application EFSA-GMO-RX-015, but reminds that monitoring is related to risk management,
and thus the ﬁnal adoption and implementation of the PMEM plan falls outside the mandate of EFSA.
4. Conclusions
Under the assumption that the DNA sequence of the event in maize MON 89034 considered for
renewal is identical to the sequence of the originally assessed event, the GMO Panel concludes that there
is no evidence in renewal application EFSA-GMO-RX-015 for new hazards, modiﬁed exposure or scientiﬁc
uncertainties that would change the conclusions of the original risk assessment on maize MON 89034.
Documentation as provided to EFSA
1) Letter from the European Commission to EFSA received on 29 August 2018 for the continued
marketing of genetically modiﬁed maize MON 89034 submitted in accordance with articles 11
and 23 of Regulation (EC) No 1829/2003 by Bayer Agriculture BVBA (EFSA-GMO-RX–015).
2) Application EFSA-GMO-RX-015 validated by EFSA, 4 December 2018.
3) Receipt of spontaneous information from the applicant, 12 December 2018.
4) Request for supplementary information to the applicant, 19 December 2018.
5) Request for supplementary information to the applicant, 29 January 2019.
6) Receipt of supplementary information from the applicant, 21 February 2019.
7) Request for supplementary information to the applicant, 11 March 2019.
8) Receipt of supplementary information from the applicant, 22 May 2019.
9) Request of clariﬁcations to the applicant, 6 June 2019.
10) Receipt of clariﬁcations requested to the applicant, 19 June 2019.
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